Recce Pharmaceuticals Ltd (ASX:RCE, FSE:R9Q) is developing a New Class of Synthetic Anti-Infectives designed to address the urgent global health problems of antibiotic-resistant superbugs and emerging viral pathogens.

Recce’s anti-infective pipeline includes three patented, broad-spectrum, synthetic polymer anti-infectives: RECCE® 327 (R327) as an intravenous and topical therapy that is being developed for the treatment of serious and potentially life-threatening infections due to Gram-positive and Gram-negative bacteria, including their superbug forms; RECCE® 435 (R435) as an orally administered therapy for bacterial infections; and RECCE® 529 (R529) for viral infections.

Through their multi-layered mechanisms of action, Recce’s anti-infectives have the potential to overcome the processes utilised by bacteria and viruses to overcome resistance – a current challenge facing existing antibiotics.

The World Health Organization (WHO) added R327, R435, and R529 to its list of antibacterial products in clinical development for priority pathogens, recognising Recce’s efforts to combat antimicrobial resistance.

The FDA granted R327 Qualified Infectious Disease Product designation under the Generating Antibiotic Initiatives Now (GAIN) Act, providing Fast Track Designation and 10 years of market exclusivity post approval. R327 is also included on The Pew Charitable Trusts’ Global New Antibiotics in Development Pipeline as the sole synthetic polymer and sepsis drug candidate in development.

Recce wholly owns its automated manufacturing, supporting current clinical trials. Recce’s anti-infective pipeline aims to address synergistic, unmet medical needs by leveraging its unique technologies.

KEY PEOPLE

  • Dr John Prendergast, Executive Chairman

    BSc (Hons), MSc (UNSW), PhD (UNSW), CSS (HU)

    Dr. Prendergast, based in the US, is a renowned executive in the pharmaceutical industry.

    Currently serving as the Chairman and Co-founder of Palatin Technologies, Inc. (NYSE: PTN) and the Lead Director of Nighthawk Biosciences (NYSE: HHWK), he brings over three decades of expertise in the commercialisation of pharmaceutical technologies.

    Dr. Prendergast has led the approval of three new drug applications and played a pivotal role in the successful sale of Vylessi® to Cosette Pharmaceuticals for USD $12M, marking a significant achievement in the pharmaceutical landscape.

    read more

  • James Graham, Managing Director & Chief Executive Officer

    BCom (Entrepreneurship), GAICD

    Mr Graham is the Chief Executive Officer of Recce Pharmaceuticals.

    He was formerly Executive Director and has extensive experience in marketing, business development and commercialisation of early-stage technologies with global potential.

    Mr Graham serves on Recce’s Board of Directors and has invested in almost every capital raise to date with a focus on expanding Recce’s commercial opportunities and clinical initiatives.

    read more

  • Michele Dilizia, Executive Director & Chief Scientific Officer

    BSc (Med Sci), Grad Dip Bus (Mkting), BA (Journ), GAICD, MASM

    Ms Dilizia is a co-inventor and qualified medical scientist with a specialisation in medical microbiology and regulatory affairs.

    She successfully co-led the research and development of Recce’s suite of anti-infective compounds, resulting in a portfolio of granted patents across the globe, including a Qualified Infectious Disease Product designation with the U.S. Food and Drug Administration (FDA).

    read more

  • Dr Alan Dunton, Chief Medical Advisor & Non-Executive Director

    BSc (BioChem) Hons, M.D. (NYU)

    Based in the US, Dr. Dunton, as the Director of Palatin Technologies, brings a wealth of experience with over three decades in senior pharmaceutical roles.

    Notably, he served as the President and Managing Director of the Janssen Research Foundation (J&J Research).

    Dr. Dunton successfully advanced multiple blockbuster antibiotics through to commercialisation at Fortune 500 companies, such as J&J and Roche, where he played instrumental roles in shaping the commercial success of pharmaceutical products.

    Dr. Dunton played a key role in the recent sale of Vylessi® to Cosette Pharmaceuticals for USD $12M, continuing his track record of fostering advancements in drug development and successful commercialisation efforts

    read more

RELATED STOCKHEAD STORIES